Diagnostics Companies Put Their Spin on The Web
Confused, like everyone else, in vitro diagnostics companies are evaluating the potential of the Internet to bring profound changes to their business. Having reacted slowly to the advent of e-business, they are just starting to venture forth with strategic planning initiatives led by high-level executives. But they have yet to decide with which portals to align.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.